Why the 2025 Tariff Hikes on Chinese Goods Won’t Impact Parimer Customers

The global trade landscape shifted again recently, when the U.S. government imposed another wave of steep tariffs on Chinese imports. Businesses across the country braced for the ripple effects: cost increases, production delays, and major disruptions across supply chains. For many, this news is triggering a mad scramble to reevaluate vendors and pricing structures. 

For Parimer and our customers, it is business as usual. One of the reasons for this is because Parimer doesn’t depend on China or any other country for its manufacturing, shipping, or assembly. Our processes are 100% based in the United States, which means our customers are completely protected from the effects of these global changes. 

These new changes leave people wondering how this will impact various industries like pharmaceutical R&D and contract manufacturing. This blog will explore that very topic.  

The April 2025 Tariff Hike: What You Need to Know 

In early April, the White House announced its latest trade action: an update to tariffs on Chinese imports, raising rates on many goods to a combined 254%. The new tariffs target high-value sectors, including: 

• Pharmaceuticals and biotech supplies 

• Consumer electronics 

• Lab and testing equipment 

• Automotive parts 

• Medical devices 

This marks one of the largest single-year increases in U.S. tariffs on China since 2018. The move was part of a broader effort to reduce U.S. dependency on foreign manufacturing and encourage reshoring. 

“These measures are aimed at protecting national interests and encouraging domestic production. The rates reflect China’s unfair practices in manufacturing and trade,” said the U.S. Trade Representative in an official statement.    

In retaliation, China announced a new round of tariffs of its own, targeting U.S. agricultural and industrial exports, raising duties on some categories to 125%.  

Pharmaceutical R&D and CDMOs: Hit the Hardest 

No industry feels this shift more sharply than pharmaceuticals and biotech, where cost and timing are everything. 

The U.S. is heavily reliant on Chinese suppliers for active pharmaceutical ingredients (APIs) and raw chemicals, many of which now face 25 - 45% tariff rates. 

“We estimate the cost of developing a new drug will rise by up to 18% due to these tariffs,” said Rachel McMillan, Senior Analyst at GlobalPharm Strategies.  

People have speculated that the increase can significantly alter the economics of innovation. New therapies may be delayed or canceled due to budget constraints. Startups and small biotech firms already stretched thin are particularly vulnerable. 

CDMOs (Contract Development and Manufacturing Organizations), many of which operate out of China, are also feeling the squeeze. They now must either absorb the added costs or pass them along to U.S. customers. 

“This is a wake-up call to diversify supply chains. Many companies are now urgently looking for U.S.-based alternatives,” said Tim Lutz, CEO of BioLogix Consulting.  

How Parimer Shields You from Global Disruption 

At Parimer, every stage of our process from concept to delivery is done within the U.S. We don’t source components from China, we don’t rely on foreign shipping lanes, and we’re not at the mercy of international politics. 

That means: 

• No price spikes 

• No shipping delays 

• No customs bottlenecks 

• No regulatory surprises 

“We’ve always believed in keeping production in the U.S. so we can control quality, timelines, and pricing. Now, more than ever, that decision is paying off for our customers,” says [Richard Pace, Owner of Parimer Scientific]. 

Many of Parimer customers who are developing complex medical devices or working within FDA-regulated industries, rely on us for precision, speed, and reliability. That’s exactly what Parimer delivers regardless of what happens on the global stage.   

The Strategic Advantage of Going Domestic 

Even before the 2025 tariff hike, many companies were beginning to rethink their reliance on overseas vendors. COVID-19, port closures, freight cost surges, and geopolitical instability have all made one thing clear: global supply chains are vulnerable. 

The new tariffs only accelerate this trend. “Companies that act now to move their supply chains onshore will be the ones who come out ahead,” said Monica Tran, Trade Economist at Brightline Global. 

Working with a domestic partner like Parimer gives businesses a unique advantage: 

• Faster prototyping and development 

• Greater IP security 

• Lower risk of disruption 

• Transparent communication and oversight 

• No hidden fees or sudden freight cost increases 

What This Means for You 

If your business is developing a medical device, drug, or other regulated product and you’re relying on Chinese parts or CDMOs you may be facing: 

• 20–30% increases in component costs 

• 4–6 week added lead time 

• Loss of control and transparency 

• Compliance and validation risks 

With Parimer, you get stability, and you get a partner who’s already positioned to thrive in this new trade environment. 

These tariffs are more than just a temporary cost bump, they signal a long-term shift in how goods are sourced and built. For companies that continue to depend on overseas suppliers, the next disruption is only a matter of time. 

Parimer will help your company with zero tariff exposure, complete transparency, and the highest quality standards in U.S.-based manufacturing.